Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma

Fig. 1

Screening and characterization of circCCAR1 in HCC. A The cluster heatmap shows the abnormal circRNAs in serum exosomes of healthy subjects and HCC patients. B A PCR assay with divergent primers was used to show the amplification of circCCAR1 from cDNA or genomic DNA (gDNA) of HCCLM3 cells. The back-splice junction sequences were verified by Sanger sequencing. C The stability of circCCAR1 and CCAR1 mRNA in HCCLM3 cells after actinomycin D treatment. ***p < 0.001 vs. CCAR1. D CCAR1 mRNA and circCCAR1 levels in HCCLM3 cells after RNase R digestion. ***p < 0.001 vs. mock. E The intracellular location of circCCAR1 in HCC cells was evaluated by a nuclear–cytoplasmic fractionation assay. F The intracellular location of circCCAR1 in HCC cells was evaluated by FISH. G Representative fluorescence images of circCCAR1 in HCC tissues and adjacent normal tissues were obtained by FISH. H The statistics for FISH. ***p < 0.001. I The level of circCCAR1 in HCC tissues and normal tissues was evaluated by qRT‒PCR assay. ***p < 0.001. J The association of circCCAR1 expression and overall survival in HCC patients. K The level of circCCAR1 in LO2 cells and HCC cell lines was measured. **p < 0.01, ***p < 0.001 vs. LO2

Back to article page